| Literature DB >> 33863887 |
Kyle Rosenke1, Frederick Hansen1, Benjamin Schwarz2, Friederike Feldmann3, Elaine Haddock1, Rebecca Rosenke3, Kent Barbian4, Kimberly Meade-White1, Atsushi Okumura1, Shanna Leventhal1, David W Hawman1, Emily Ricotta5, Catharine M Bosio2, Craig Martens4, Greg Saturday3, Heinz Feldmann6, Michael A Jarvis7,8,9.
Abstract
The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication is observed in animals when the drug is administered either beginning 12 h before or 12 h following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients.Entities:
Year: 2021 PMID： 33863887 DOI： 10.1038/s41467-021-22580-8
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919